• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
BYL719

BYL719

Product ID B9700
Cas No. 1217486-61-7
Purity ≥99%, ≥99%ee
Product Unit SizeCostQuantityStock
1 mg $63.00 In stock
5 mg $115.50 In stock
25 mg $173.30 In stock
100 mg $446.30 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

BYL-719 is an ATP-competitive oral PI3K inhibitor selective for the p110α isoform that is activated by a mutant PIK3CA gene in HER2+ breast cancers and gastric cancers. BYL-719 exhibits anticancer chemotherapeutic activity and inhibits proliferation in a variety of cell lines. IGF1 and neuregulin 1 activate mTOR, a downstream target of PI3K that mediates resistance to BYL-719 in some in vitro cancer models. This compound also decreases invasion and epithelial-to-mesenchymal transition (EMT) in cellular and animal models of squamous cell lung cancer.

Product Info

Cas No.

1217486-61-7

Purity

≥99%, ≥99%ee

Formula

C19H22F3N5O2S

Formula Wt.

441.47

Chemical Name

(2S)-1-N-[4-methyl-5-[2-(1,1, 1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1, 3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide

IUPAC Name

(2S)-1-N-[4-methyl-5-[2-(1,1, 1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1, 3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide

Synonym

Alpelisib, NVP-BYL719, BYL-719

Solubility

DMSO 88 mg/mL (199.33 mM) Ethanol 2 mg/mL (4.53 mM) Water Insoluble

Appearance

White Crystal Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

B9700 MSDS PDF

Info Sheet

B9700 Info Sheet PDF

References

Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

Elkabets M, Vora S, Juric D, et al. mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer. Sci Transl Med. 2013 Jul 31;5(196):196ra99. PMID: 23903756.

Abstract: Juric. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. American Association for Cancer Research. 2012.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • T5608

    α-Tocotrienol

    Antioxidant, vitamin E derivative found in vege...

    ≥98%
  • D3353

    Diminazene Aceturate

    Diamidine; ACE2 activator, DNA polymerase inhib...

    ≥98%
  • L3550

    Limonin

    Furanolactone found in citrus fruits.

    ≥98%
  • T8145

    Tulobuterol Hydrochloride

    β2-adrenergic agonist.

    ≥98%
  • P2002

    PF-04691502 Dihydrate

    PI3K and mTOR inhibitor.

    ≥98%
  • C084099

    CCCP

    Efflux pump inhibitor

    ≥99%
  • T3040

    Thienylpentyl Isothiocyanate

    Thienylbutyl ITC analog.

    ≥98%
  • T0250

    Tamoxifen Citrate

    4-Hydroxytamoxifen prodrug; FIASMA, SERM, PKC i...

    ≥98%
  • K5604

    Kobe 0065

    Ras inhibitor.

    ≥99%
  • T3202

    Tianeptine

    μOR and δOR agonist, D2/D3 DA potentiator.

    ≥98%
  • T3034

    Thienylethyl Isothiocyanate

    Thienylbutyl ITC analog.

    ≥98%
  • M184790

    Metyrapone

    Steroidogenesis inhibitor

    ≥98%
  • C086007

    CC-671

    TTK/CLK2 inhibitor.

    ≥98%
  • T6817

    D(+)-Trehalose Dihydrate

    α-Linked disaccharide composed of α-glucose u...

    ≥98%
  • E7209

    Escitalopram Oxalate

    S-enantiomer of citalopram; SERT inhibitor.

    ≥99%
  • D1629

    Dehydroepiandrosterone

    Endogenous steroid hormone; ERβ, NMDA, σ1 ago...

    ≥98%
  • A5045

    Amlodipine

    Dihydropyridine, FIASMA; L-type Ca2+ channel bl...

    ≥98%
  • A5056

    Amorolfine Hydrochloride

    14α-demethylase inhibitor.

    ≥98.5%
  • A7672

    Atropine Sulfate Monohydrate

    Tropane alkaloid found in Solanaceae plants; mA...

    ≥98%
  • H3272

    His Tag

    Six-histidine peptide used for affinity column ...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only